Logo

American Heart Association

  112
  0


Final ID: Su3027

Prevalence, Incidence, and Progression of Cardiovascular-Kidney-Metabolic Syndrome in a Diverse Nationwide Cohort

Abstract Body (Do not enter title and authors here): Introduction:
Recent studies using cross-sectional survey data have suggested high prevalence of cardiovascular-metabolic-kidney syndrome in the United States. However, these studies are limited by their cross-sectional design and cannot estimate progression or incidence reliably. In this study, we use the longitudinal nature of the AllofUs cohort to estimate the incidence and observe the progression and impact of CKM syndrome stages within a diverse cohort.
Research Aims:
To understand the distribution and impact of various stages of CKM syndrome within a diverse population cohort over an extended period and identify risk factors for CKM progression.
Methods/Approach:
Utilizing data from the AllofUs Research platform, we conducted a longitudinal analysis of patients within the cohort. Prevalence was calculated annually, while incidence was estimated by identifying new diagnoses of CKM syndrome. The incidence rate was calculated as the number of new diagnoses over the number of people at risk of developing that stage, using a one-year look-back window. We defined CKM stages according to recent AHA criteria, and additionally created three additional stages, which we termed Stage 5 (CVD and CKD stage 3-5), Stage 6 (>=2 CVD and CKD stage 3-5), and Stage 7 CKM (>=2 CVD, CKD stage 3-5, and >= one metabolic risk factor).
Results:
Our analysis revealed that the prevalence of CKM syndrome increased over the study period. For instance, the prevalence of Stage 1 CKM syndrome increased from 64.7% in 2018 to 80.18% in 2021, while Stage 2 CKM syndrome rose from 84.5% in 2018 to 92.91% in 2021. The incidence of various CKM stages in 2021 are shown in Table 1. The prevalence of all CKM stages are shown in Figure 1. At the conference, we will present models of risk factors for progression of CKM over time.
Conclusions: More than 9 in 10 participants in a large nationwide cohort had Stage 2 CKM and the annual incidence of CKM ranged from 12% for Stage 1 CKM to ~3% for stage 4 CKM.
  • Tan, Savannah Xinyi  ( Duke University , Durham , North Carolina , United States )
  • Li, Fan  ( Duke University , Durham , North Carolina , United States )
  • Mac Grory, Brian  ( Duke University , Durham , North Carolina , United States )
  • Lusk, Jay  ( Duke University , Durham , North Carolina , United States )
  • Author Disclosures:
    Savannah Xinyi Tan: DO NOT have relevant financial relationships | Fan Li: DO NOT have relevant financial relationships | Brian Mac Grory: No Answer | Jay Lusk: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Translating the Concept of CKM Syndrome to Real-World Populations

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Associations of Ideal Cardiovascular Health and Its Change With Cardiovascular-Kidney Outcomes in Young Adults

Lee Hokyou, Lee Hyeok-hee, Jhee Jong Hyun, Kim Eun Jin, Kim Hyeon Chang, Lloyd-jones Donald

Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study

Lee Matthew, Malik Fady, Kupfer Stuart, Wohltman Amy, Coats Caroline, Abraham Theodore, Claggett Brian, Maron Martin, Miao Zi, Meder Benjamin, Olivotto Iacopo, Heitner Stephen, Jacoby Daniel

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available